- The shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have received an $85 price target from Goldman Sachs. These are the details.
The shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have received an $85 price target from Goldman Sachs. And Goldman Sachs analyst Madhu Kumar assumed coverage of Arrowhead Pharmaceuticals with a “Buy” while reducing the price target from $90.
Kumar had recognized the RNAi pipeline opportunity from Arrowhead’s TRiM platform and was impressed by ARO-AAT in AAT PiZZ liver disease and ARO-APOC3/ARO-ANG3/olpasiran in cardio-metabolic conditions as potentially best-in-class programs in their respective spaces.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
